林业发展局批准Imfinzi对有限阶段的小型细胞肺癌进行免疫治疗,为这种类型的首次免疫疗法打上标记。 FDA approves Imfinzi for limited-stage small cell lung cancer, marking first immunotherapy for this type.

林业发展局批准AstraZeneca公司批准Imfinzi(durvalumab)治疗患有小细胞肺癌(LS-SCLC)的成人,在最初的化疗和辐射后,该病没有进展。 The FDA has approved Imfinzi (durvalumab) by AstraZeneca for treating adults with limited-stage small cell lung cancer (LS-SCLC) that has not progressed after initial chemotherapy and radiation. 根据ADRIATIC试验,Imfinzi将死亡风险降低27%,中位存活率为55.9个月,而安慰剂的存活率为33.4个月。 Based on the ADRIATIC trial, Imfinzi reduced the risk of death by 27% with a median survival of 55.9 months compared to 33.4 months with a placebo. 这一批准标志着LS-SCLC的首次免疫疗法治疗,为传统化疗提供了替代方案,并有可能提高存活率。 This approval marks the first immunotherapy treatment for LS-SCLC, offering an alternative to traditional chemotherapy and potentially improving survival rates.